Key Highlights

● Altimmune appointed Richard Menziuso, age 51, as Vice President, Global Controller and Principal Accounting Officer effective September 29, 2026.

● Gregory Weaver will remain Chief Financial Officer, so the filing describes no change in that position.

● From 2021 to 2026 he was Vice President, Corporate Controller at Centessa Pharmaceuticals, according to the filing.

● Altimmune will enter into an indemnification agreement with him in the form filed as Exhibit 10.7 to its 2025 10-K.

Altimmune, Inc. (NASDAQ:ALT) reported in a Form 8-K filed on September 29, 2026 that it has appointed Richard Menziuso, age 51, as Vice President, Global Controller and Principal Accounting Officer, effective September 29, 2026. The filing states that Gregory Weaver will remain the company's Chief Financial Officer. The report is filed under Item 5.02, which covers the appointment of certain officers, and it is signed by Mr. Weaver.

The Appointment

Principal Accounting Officer is one of the officer positions that companies must identify in their SEC filings, and Item 5.02 requires a report when someone is appointed to it. According to the 8-K, Mr. Menziuso takes the title of Vice President, Global Controller together with that designation. The report date on the filing is September 24, 2026, and the appointment took effect on September 29, 2026, the same day the 8-K was filed.

The filing does not identify who previously held the principal accounting officer designation, and it does not describe why the position is being filled now. It does state plainly that Mr. Weaver will remain Chief Financial Officer, so the filing describes no change to the company's Chief Financial Officer.

Mr. Menziuso's Background and Disclosures

The filing names Centessa Pharmaceuticals plc (NASDAQ:CNTA) as his most recent employer, and it lays out his career in reverse order of employment from that role, together with his education and professional credentials. The 8-K says Mr. Menziuso has 28 years of finance and accounting experience, including 12 years in public accounting. From 2021 to 2026 he was Vice President, Corporate Controller at Centessa Pharmaceuticals plc. Before that he was North America Controller and Head of Global Finance Customer Solutions at Thermo Fisher Scientific (NYSE:TMO) from 2019 to 2021, and Vice President, Accounting and Controller at Axovant Gene Therapies from 2017 to 2019.

His earlier roles included positions at LifeCell Corporation, ConvaTec Healthcare, Tyco International, PricewaterhouseCoopers and Bristol-Myers Squibb (NYSE:BMY). The filing says he holds a Bachelor of Business Administration degree in public accounting from Pace University and is a Certified Public Accountant and a Chartered Global Management Accountant.

The filing includes the customary statements about relationships and arrangements. It says there is no arrangement or understanding between Mr. Menziuso and any other person under which he was selected, no family relationship between him and any director or executive officer of the company, and no transactions requiring disclosure under the related-party rules. It also states that Altimmune will enter into an indemnification agreement with him in the form filed as Exhibit 10.7 to the company's 2025 Annual Report on Form 10-K.

What the Filing Does Not Disclose

The 8-K does not disclose Mr. Menziuso's salary, bonus opportunity, equity awards or the terms of any offer letter or employment agreement. It does not describe his reporting line. It also does not include financial results, guidance or any discussion of clinical or business developments.

Gregory Weaver, Chief Financial Officer, signed the report on September 29, 2026. It does not say whether an outside search was conducted, whether he will hold any additional title, or which periodic report he is first expected to sign.

Altimmune's Accounting Leadership Under Menziuso

The appointment is already effective, and Mr. Weaver will remain Chief Financial Officer alongside Mr. Menziuso as Principal Accounting Officer.